Products & Services
Research & Specialties
Custom Peptide Synthesis
Amino Acid Derivatives
Services & Capabilities
Quality & Regulatory
Research Grade Production
Supply & vertical integration
Our vision & strategy
People & culture
Safeguarding the environment
Investors & Media
Reports & Presentations
News & Events
Key figures for capital increase as announced
April 23, 2019
Only available in the German version.
Annual General Meeting approves all Board proposals
Peptide Trends April 2019
A world market leader from the Basel region – Bachem celebrates 50 years of company history
What are Amino Acids?
Bachem recognized as a winner at the Swiss Biotech Success Stories Awards 2021
What is GMP?
Amyloid Beta Peptides & Alzheimer’s Disease
Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson’s Disease?
Meet Bachem: Swetlana Meinhardt, Category Manager
Peptides unlock doors to understand Parkinson’s disease
Interview with Robert Yu, CEO of Yuyu Pharma
What are peptides?
Bachem celebrates the hire of its 1000th employee at the Bubendorf site
GalNAc: Delivering Promise of Oligonucleotides
Bachem appoints new Head of Group Communications
Meet Bachem: Johannes Kremser, Group Leader R&D
GalNAc conjugates: Delivery service to the liver!
Bachem announces the launch of their new website
Change in the Board of Directors of Bachem Holding AG
Bachem reports excellent results in 2020 – Sales exceed 400 million CHF for the first time
Peptide Trends February 2021